Background: In our preliminary study, the modified Marsh (M-Marsh) model caused an inadvertent underdosing of propofol in underweight patients. However, the predictive performance of the M-Marsh and Schnider models incorporated in commercially available target-controlled infusion (TCI) pumps was not evaluated in underweight patients. Methods: Thirty underweight patients undergoing elective surgery were randomly allocated to receive propofol via TCI using the M-Marsh or Schnider models. The target effect-site concentrations (Ces) of propofol were, in order, 2.5, 3, 4, 5, 6 and 2 lg ml
Key words: model; pharmacokinetics; propofol; underweight Target-controlled infusion (TCI) systems use pharmacokinetic models to control the plasma or effect-site concentrations (Ces) of hypnotics and opioids during general anaesthesia. The modified Marsh and Schnider models are commonly used to determine the infusion rates for user-selected Ce values of propofol. 1 2 The former uses the pharmacokinetic parameters estimated by Marsh and colleagues 3 (which were modified from those estimated by Gepts and colleagues 4 ) and the plasma effect-site equilibration rate constant (k e0 ) of 1.21 min À1 explored by Struys and colleagues 5 whereas the latter was derived from a single population using combined pharmacokinetic-pharmacodynamic modelling. 6 7 Although external validation studies have demonstrated that both models are clinically acceptable, 8 9 our experience suggests that use of the modified Marsh model might cause inadvertent underdosing of propofol in underweight patients. In our preliminary data, general anaesthesia was maintained at a propofol target Ce of 2.5 lg ml À1 using the modified Marsh model, and the amount of i.v. midazolam and mean infusion rate of remifentanil during anaesthesia were significantly higher in underweight patients than in normal weight patients. To the best of our knowledge, the predictive performance of the two models has not been evaluated in underweight patients. In general, a patient is determined to be underweight based on his or her BMI, 10 and adults with a BMI of <18.5 kg m À2 are defined as underweight according to the World Health Organisation. 11 In an earlier large-scale study, underweight patients comprised 2.4% of all patients undergoing major surgery for the treatment of intra-abdominal cancer, 12 and these patients had a five-fold higher risk of mortality than patients of normal weight. 12 From social and medical perspectives, however, obesity tends to receive more attention than an underweight status, although greater attention to underweight patients undergoing general surgery is clearly necessary. This study compared the predictive performance of the modified Marsh and Schnider pharmacokinetic models in underweight patients undergoing elective surgery under general anaesthesia using TCI.
Methods

Patient population
This prospective clinical trial was conducted from March 2013 to August 2014. The study protocol was approved by the Institutional Review Board of the Asan Medical Centre (2013 À 0077, Seoul, Korea), and registered on an international clinical trials registry platform (http://cris.nih.go. kr, KCT0001502). Thirty ASA Physical Status I or II underweight patients who were scheduled for elective surgery were randomly allocated to receive propofol using the modified Marsh (n¼15) or Schnider models (n¼15). Patients with a known allergy to propofol, abnormal laboratory findings with clinical significance or evidence of pregnancy were excluded.
Procedure
All patients fasted from midnight on the day of surgery without premedication. In the operating room, they were monitored using ECG, pulse oximetry, end-tidal carbon dioxide partial pressure, non-invasive blood pressure (Datex-Ohmeda S/5, Planar Systems, Inc., Beaverton, OR, USA) and the bispectral index. Each patient was pre-oxygenated with 100% oxygen via a facemask. The patients received propofol via a target Cecontrolled infusion using the modified Marsh or Schnider models. 4 5 Remifentanil was administered via a target Ce-controlled infusion using the Minto model. 13 The concentration maintained for at least 7 min after the achievement of a pseudo-steady-state between the blood and brain ( Supplementary Fig. S1 ). If necessary, ephedrine, phenylephrine or atropine was administered to maintain a SBP of !80 mm Hg and a HR of !45 beats min À1 during anaesthesia.
Neuromuscular blockade was reversed via the administration of neostigmine and glycopyrrolate at the end of surgery.
Blood sampling and plasma concentration assay
Arterial blood samples (3 ml) were obtained at least 7 min after achieving a pseudo-steady-state of each concentration, 2.5, 3, 4, 5, 6 and 2 lg ml À1 . Each sample was collected in a tube containing ethylenediaminetetraacetic acid and centrifuged for 10 min at 252g; the plasma was stored at À70 C until required for the assay. Plasma concentrations of propofol were analysed using ultrafast lipid chromatography (Shimadzu, Kyoto, Japan) coupled with tandem mass spectrometry (API5500, SCIEX, Framingham, MA, USA Editor's key points
• The Marsh and Schnider propofol models were developed from data from healthy adults.
• The authors studied their predictive performance during TCI propofol administration in underweight patients.
• The Marsh model showed a significant negative bias (underprediction) and the Schnider a small positive bias.
• The overall predictive performance of the Eleveld, modified Marsh and Schnider models was similar.
ml
À1 . The within-run accuracy ranged from 98.3% to 99.6%, and the between-run accuracy ranged from 97.8% to 102.5%. The within-run and between-run precision levels, expressed as % coefficient of variation (CV), were <2.1% and <3.0%, respectively, validating the plasma concentration analysis method over the specified quantification range.
Performance analysis
As described in earlier reports, 14 15 the predictive performance of the TCI system was characterized via the calculation of four parameters: inaccuracy, divergence, bias and wobble. 16 First, for each blood sample, the performance error (PE) of the ith patient was calculated as follows:
where predicted ij is the predicted effect-site propofol concentration at the jth sampling point from the ith patient, and measured ij is the observed plasma propofol concentration at the jth sampling point from the ith patient. The inaccuracy of a TCI system (i.e. the size of the typical miss) for the ith individual was calculated as the median absolute PE (MDAPE i ):
where N i is the number of blood sampling points for the ith individual. Divergence, a measure of the expected systematic timerelated changes in performance, was calculated for the ith individual as the slope obtained from the linear regression of the jPE ij j values of that individual against time:
where t ij is the time (in min) at which the corresponding PE ij was determined. The third performance measurement, bias (i.e. the direction and size of the deviation from the target) for the ith individual, was calculated as the median PE (MDPE i ):
The fourth performance measurement, wobble i for the ith individual, was a measure of the variability of the PE ij in that individual:
A pooled data approach was used to obtain the population estimate for MDAPE, divergence, bias and wobble (fit4NM 3.3.3, E.K.L. and G.J.N.; http://cran.r-project.org/web/packages/fit4NM/ index.html, last accessed: March 16, 2011). 16 We pooled the measured plasma concentrations in patients receiving propofol via target Ce-controlled infusion using the modified Marsh or Schnider models, because concurrent medication including remifentanil, ephedrine and/or phenylephrine might influence the pharmacokinetics of propofol. An assessment of the predictive performance of the modified Marsh, Schnider and Eleveld models was performed using the plasma concentrations retrospectively estimated for each model. The Eleveld model is a pharmacokinetic model that was recently proposed to cover a wide range of patients (from paediatric to elderly and from lean to obese), and showed an improved inaccuracy in obese patients. 17 
Simulations
Deterministic simulations, which consider neither interindividual nor intra-individual random variability, were performed using Asan Pump version 2.1.3 software (Bionet Co. Ltd, http://www.fit4nm.org/download, last accessed: June 24, 2014). First, propofol clearance of both models was simulated according to the change in BMI. Second, the cumulative doses of propofol necessary to achieve and maintain a target Ce of 2-6 lg ml À1 for 10 min using both models were simulated for compari- 
Statistical analyses
Statistical analyses were conducted using R (version 3.1.2, R Foundation for Statistical Computing, Vienna, Austria) or SigmaStat version 3.5 for Windows (Systat Software, Inc., Chicago, IL, USA). Data are expressed as the mean SD for normally distributed continuous variables, the median (25 À 75%) for non-normally distributed continuous variables, or counts and percentages for categorical variables. A P-value of < 0.05 was considered statistically significant.
Results
The characteristics of the study population are summarized in Table 1 . In total, 172 plasma samples (84 samples at target Ce values of 2, 2.5 and 3 lg ml À1 and 88 samples at target Ce values of 4, 5 and 6 lg ml À1 ) obtained from 30 underweight patients were used to determine the predictive performance of the pharmacokinetic models. Eight samples from four patients were not obtained because of the relatively brief duration of the surgery. The mean duration of propofol administration at each target Ce over time and the cumulative dose of propofol at the time of blood sample acquisition are presented in Supplementary data, Fig. S1 . The infusion duration of propofol at each target Ce did not differ between the two groups; however, the cumulative doses of propofol in the Schnider model were larger than those in the modified Marsh model. SBP at the time of blood sample acquisition showed no differences between the two groups ( Supplementary Fig. S1 ). Ephedrine (5 mg) was administered five times for four patients using the modified Marsh model and 10 times for seven patients using the Schnider model. Phenylephrine (100 lg) was administered three times for two patients using the modified Marsh model and five times for four patients using the Schnider model. No significant differences were found with regards to the number of patients who received these drugs between the two groups (v 2 test). Concurrent medications and laboratory tests are summarized in Supplementary data, Table S1 . The amount of remifentanil infused at each target Ce of propofol did not show any significant differences between the two groups (Supplementary Table S2 ).
The measured vs predicted propofol concentrations for the modified Marsh and Schnider models are presented in Figure 1 . This plot shows a significant underprediction of the plasma propofol concentrations by the Schnider model but significant overprediction by the modified Marsh model. The measured-topredicted propofol concentration ratio of the modified Marsh, Schnider and Eleveld models are presented in Figure 2 . Pooled biases, inaccuracies, divergences and wobbles of the modified Marsh, Schnider and Eleveld models for propofol in underweight patients are shown in Table 2 . Overall, the pooled bias and inaccuracy of the Schnider model were smaller than those of the modified Marsh model at target Ce values of 2, 2.5 and 3 lg ml À1 but greater at target Ce values of 4, 5 and 6 lg ml
À1
. The predictive performance of the Eleveld model was similar to the modified Marsh and Schnider models. The 95% confidence intervals of MDPE did not include zero in either model, indicating significant bias. However, the overall pooled bias and inaccuracy in the predictions of both models were within the clinically acceptable range as described in earlier studies (MDPE <10-20% and MDAPE 20-40%). 8 15 19 20 The divergence and wobble associated with the predictions of both models were comparable with those found in earlier studies. 8 21 The simulated clearances in the modified Marsh and Schnider models based on the change in BMI are shown in Figure 3 . The clearance in the Schnider model was consistently higher than that in the modified Marsh model, particularly in subjects with a BMI of <18.5 kg m À2 . The simulated weightnormalized doses of propofol required to achieve and maintain a target Ce of 2-6 lg ml À1 for 10 min using both models are shown in Supplementary data, Fig. S2 . The weight-normalized doses of propofol in underweight patients were comparable with those in normal weight patients in the modified Marsh model. However, in the Schnider model, the weight-normalized propofol dose was higher in underweight patients, and the difference with normal weight patients increased at a higher target Ce. The simulated infusion rates over time to maintain a target Ce of 3 lg ml À1 for 60 min for the three models are shown in Figure 4 . The infusion rates of the modified Marsh and Eleveld models were higher in the normal weight patients whereas the infusion rates of the Schnider model were almost the same in normal weight and underweight patients.
Discussion
Adults might be underweight because of a lack of food, illness (e.g. cancer or inflammatory bowel disease) or psychological factors (e.g. anorexia nervosa or bulimia). 10 22 23 Low body weight is a term simply describing that a person's weight is low whereas the definition of underweight usually refers to a person whose weight is low for their height (BMI <18.5 kg m À2 ).
There are subtle but important differences in the way that the Marsh and Schnider models deal with body weight. 3 6 7 The
Marsh model scales compartmental volumes according to total body weight (TBW) and has fixed re-distribution and metabolic rate constants. Thus, this model will predict the same metabolic clearance rate (in terms of ml kg À1 hr À1 ) for all patients. By contrast, the Schnider model has fixed V 1 and V 3 , and the only parameters influenced by body weight are the metabolic rate constant and by definition the metabolic clearance. The metabolic rate constant depends on TBW, height and lean body mass (LBM). LBM is calculated by the James equation, a quadratic function that uses gender, TBW and height to calculate LBM. 24 As a result of these equations, the Schnider model will predict higher metabolic clearance rates (in ml kg À1 min À1 )
for underweight patients than for normal and obese patients; and indeed for underweight patients, the Schnider model will calculate higher metabolic clearance rates than will the Marsh model. In general, the different clearance values are important pharmacokinetic parameters for determining the rate of infusion to maintain a target concentration. Before equilibrium between the different model compartments is reached, a stable plasma concentration can be maintained if in each unit of time the infusion system replaces drug removed from the central compartment by fast re-distribution, slow re-distribution and metabolic clearance. Fast re-distribution clearance is calculated as the product V 1 Â k 12 , slow re-distribution clearance is calculated as the product V 1 Â k 13 , and metabolic clearance is calculated as the product V 1 Â k 10 . For the Schnider model, as opposed to the Marsh model, fast and slow metabolic clearance do not decrease with decreasing weight. For patients of normal weight, the calculated re-distribution clearance rates are similar for the two models. However, for underweight patients, the Schnider model will calculate higher re-distribution clearance rates than the Marsh model. Over time the net movement of drug between V 1 and V 2 , and between V 1 and V 3 , reduces towards zero, so that eventually, the infusion rate required to maintain stable plasma concentrations depends only on the product V 1 Â k 10 , and, as shown in Figures 3 and 4 , the metabolic clearance estimated by the Schnider model in underweight patients is higher than that of the modified Marsh model, indicating that the infusion rate required to maintain a given target concentration is higher with the former than the latter model. When considering the target Ce level, the performance of the Schnider model was better at a target Ce 3 lg ml À1 whereas it was better in the modified Marsh model at a target Ce !4 lg ml
À1
. The simulated cumulative doses of propofol revealed that the Schnider model had a tendency to infuse a higher Dose cum_W in underweight patients as the target Ce was increased (see Supplementary Fig. S2 ). This tendency might explain the relatively poor predictive performance of the Schnider model at the target Ce values of 4, 5 and 6 lg ml
. The reduction of negative bias at higher concentrations was also observed in the modified Marsh model ( Table 2 ). The tendency for increased positive bias or reduced negative bias at higher target concentrations has been reported in previous studies.
8 19 25 Bias change in both models in the same direction at higher target concentrations could be explained by incomplete mixing of propofol in the systemic circulation, which occurs at a high rate of drug delivery. 19 25 Although it is generally assumed that propofol is instantaneously distributed at the time of administration, the fact that arterial and venous concentrations during propofol infusion differ suggests the possibility of incomplete mixing of propofol in the systemic circulation. 26 The inter-individual variability in the pharmacokinetics of propofol, errors in the sampling technique and the trapping of propofol in the lungs may be proposed as other possible causes.
27
The effects of patients' coexisting conditions, such as concurrent medication or preoperative liver function, should also be considered when evaluating the performance of both models. We compared concurrent medications and laboratory test results between the two groups, and the results were comparable (Supplementary Table S2 ). To the best of our knowledge, no previous reports have addressed the drug interaction between propofol and major concurrent medications, such as azathioprine or mercaptopurine, in patients. The major route of propofol metabolism is glucuronidation mediated by uridine diphosphate glucuronosyltransferase 1A9. 28 29 Meanwhile, thiopurine agents such as azathioprine and mercaptopurine undergo hepatic metabolism by different enzymatic pathways, mainly involving xanthine oxidase. 30 31 In conclusion, the pooled biases and inaccuracies of the modified Marsh and Schnider models were clinically acceptable. However, the modified Marsh and Schnider models consistently produced negatively and positively biased predictions, respectively, in underweight patients. In particular, the modified Marsh model showed greater inaccuracy at a target Ce 3 lg ml À1 and the Schnider model showed greater inaccuracy at a target Ce !4 lg ml
À1
. These discrepancies in both models are mainly due to the difference in estimated clearance. The predictive performance of the Eleveld model was similar to that of the modified Marsh and Schnider models. Therefore, it is necessary to develop a new pharmacokinetic model for propofol in underweight patients.
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